198 related articles for article (PubMed ID: 20856796)
1. Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice.
Jögi A; Rønø B; Lund IK; Nielsen BS; Ploug M; Høyer-Hansen G; Rømer J; Lund LR
PLoS One; 2010 Sep; 5(9):e12746. PubMed ID: 20856796
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
3. Promotion of Wound Healing by an Agonist of Adenosine A2A Receptor Is Dependent on Tissue Plasminogen Activator.
Montesinos MC; Desai-Merchant A; Cronstein BN
Inflammation; 2015 Dec; 38(6):2036-41. PubMed ID: 25991438
[TBL] [Abstract][Full Text] [Related]
4. Mice deficient in urokinase-type plasminogen activator have delayed healing of tympanic membrane perforations.
Shen Y; Guo Y; Du C; Wilczynska M; Hellström S; Ny T
PLoS One; 2012; 7(12):e51303. PubMed ID: 23236466
[TBL] [Abstract][Full Text] [Related]
5. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo.
Lund IK; Jögi A; Rønø B; Rasch MG; Lund LR; Almholt K; Gårdsvoll H; Behrendt N; Rømer J; Høyer-Hansen G
J Biol Chem; 2008 Nov; 283(47):32506-15. PubMed ID: 18799467
[TBL] [Abstract][Full Text] [Related]
6. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator.
Schäfer K; Konstantinides S; Riedel C; Thinnes T; Müller K; Dellas C; Hasenfuss G; Loskutoff DJ
Circulation; 2002 Oct; 106(14):1847-52. PubMed ID: 12356640
[TBL] [Abstract][Full Text] [Related]
7. Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
Chintala SK
Exp Eye Res; 2016 Feb; 143():17-27. PubMed ID: 26474495
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190
[TBL] [Abstract][Full Text] [Related]
9. Studies of mice lacking plasminogen activator gene function suggest that plasmin production prior to ovulation exceeds the amount needed for optimal ovulation efficiency.
Ny A; Nordström L; Carmeliet P; Ny T
Eur J Biochem; 1997 Mar; 244(2):487-93. PubMed ID: 9119016
[TBL] [Abstract][Full Text] [Related]
10. Increased bone formation in mice lacking plasminogen activators.
Daci E; Everts V; Torrekens S; Van Herck E; Tigchelaar-Gutterr W; Bouillon R; Carmeliet G
J Bone Miner Res; 2003 Jul; 18(7):1167-76. PubMed ID: 12854826
[TBL] [Abstract][Full Text] [Related]
11. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
12. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
14. Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblastic proliferation and vascular endothelial growth factor.
Kawao N; Tamura Y; Okumoto K; Yano M; Okada K; Matsuo O; Kaji H
Am J Physiol Endocrinol Metab; 2014 Aug; 307(3):E278-88. PubMed ID: 24918201
[TBL] [Abstract][Full Text] [Related]
15. Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo.
Suelves M; López-Alemany R; Lluís F; Aniorte G; Serrano E; Parra M; Carmeliet P; Muñoz-Cánoves P
Blood; 2002 Apr; 99(8):2835-44. PubMed ID: 11929773
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activation in healing human wounds.
Schäfer BM; Maier K; Eickhoff U; Todd RF; Kramer MD
Am J Pathol; 1994 Jun; 144(6):1269-80. PubMed ID: 8203466
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of corneal epithelial defects: role of plasminogen activator.
Hayashi K; Berman M; Smith D; el-Ghatit A; Pease S; Kenyon KR
Curr Eye Res; 1991 May; 10(5):381-98. PubMed ID: 1909616
[TBL] [Abstract][Full Text] [Related]
18. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.
Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS
Am J Physiol Heart Circ Physiol; 2001 Oct; 281(4):H1784-92. PubMed ID: 11557572
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice.
Cooper JM; Rastogi A; Krizo JA; Mintz EM; Prosser RA
Eur J Neurosci; 2017 Mar; 45(6):805-815. PubMed ID: 27992087
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic overlap between MMP-13 and the plasminogen activation system during wound healing in mice.
Juncker-Jensen A; Lund LR
PLoS One; 2011 Feb; 6(2):e16954. PubMed ID: 21326869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
